Logo
x

Search category

Subscribe Now

marketing application

Roche Reports EMA and FDA's Acceptance of Marketing Application for Satralizumab to Treat Neuromyelitis Optica Spectrum Disorder

Roche Reports EMA and FDA's Acceptance of Marketing Application for Satralizumab to Treat Neuromyelitis Optica Spectrum Disorder

  • October 30, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.